The eye has its own connectome, the neuronal network of the retina that processes the incoming signals before it sends them off to the brain. Much of its structure is yet unknown, and now researchers are looking into the powers of crowdsourcing to proc…
Category: News
New data from Acucela’s ACU-4429 Phase 2a trial on advanced dry AMD/geographic atrophy
Acucela Inc., a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, announced today that the first patient data from the ACU-4429 program were presented during a poster session at The Association for Res…
Transplanting Whole Cornea Not Always Necessary
Worldwide, corneas are the most frequently transplanted tissue. However, because of rapid advances, the long-developed technique of complete transplantation, i.e. penetrating keratorplasty (PK) is no longer necessary in many instances…
Ranibizumab Equivalent to Bevacizumab for Treating Wet AMD
Two-year results from the Comparison of Age-related Macular Degeneration Treatments Trials showed that ranibizumab was equivalent to bevacizumab for treating neovascular AMD. Medscape Medical News
Age-Related Macular Degeneration – How To Tackle Increasing Rates
With aging populations, age-related macular degeneration (AMD) is set to increase. AMD, which causes progressive blindness, may already be present in the early stages in 20% of 60 year-olds and those who are older in some countries…
No functional difference in effects of Lucentis and Avastin on preventing vision loss
The one year results from a study into whether two drug treatments (Lucentis and Avastin), are equally effective in treating neovascular or wet age-related macular degeneration (wet AMD), have been reported today at an international research meeting in…
Oral nutriceutical restores vision to otherwise hopeless patients facing permanent loss
There may be new found hope for patients whose vision is threatened when medicine injected directly into the eyes fails to cause abnormal blood vessels to recede. While injectable drugs called angiogenesis (an-gee-oh-jen-esis) inhibitors are considered…
First Oral Agent To Quell Invasive Macular Degeneration, Restore Lost Vision
There may be new found hope for patients whose vision is threatened when medicine injected directly into the eyes fails to cause abnormal blood vessels to recede. While injectable drugs called angiogenesis (an-gee-oh-jen-esis) inhibitors are considered…
Myopia, Short-sightedness Rates Very High In East Asia
Around 80% to 90% of school-leavers in major East Asian cities like China, Taiwan, Hong Kong, Japan, Singapore and South Korea suffer from myopia or short-sightedness…
Dispelling Myths in Refractive Surgery
Some of the most persistent myths about LASIK are tackled, and the truth should be a relief to practicing refractive surgeons. Medscape Ophthalmology
Bionic eye helps two blind men see for the first time in 20 years
In a medical breakthrough two blind men have regained partial sight for the first time in more than 20 years after receiving a “bionic eye”. Scientists said the first clinical trials of the microchip eye implant, which measures just 3mm across and …
New Phakic Intraocular Lens Is Effective and Safe
Five-year data indicate that patients implanted with the new phakic lens continue to have excellent visual acuity and stable refraction. Medscape Medical News
Second-Generation Glaucoma Stents Are Effective and Safe
A new study reports impressive results with second-generation glaucoma stents in patients with mild to moderate open-angle glaucoma. Medscape Medical News
STAAR Surgical first quarter total revenue increases 4% to $15.5M
STAAR Surgical Company, a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today reported that sales of its Visian ICL product in the first quarter ended March 30, 2012 increased 25% to $8.6 million.
Levetiracetam to be tested for seizure management in malaria endemic regions
Michigan State University researchers, with the help of a groundbreaking medical device, are starting a clinical trial in Africa they hope will provide relief for the hundreds of thousands of children who survive cerebral malaria but are left stricken …
Interpreting The Avastin-Lucentis Study For Persons With Macular Degeneration
This week, the second-year results of an important clinical trial on age-related macular degeneration (AMD), known as the Comparison of AMD Treatments Trials (or CATT), were published in the journal Ophthalmology. Researchers found that two drugs known…
Bevacizumab equivalent to ranibizumab in treating wet AMD
In a landmark drug-comparison study, Cleveland Clinic researchers found that bevacizumab (Avastin) is equivalent to ranibizumab (Lucentis) in the treatment of wet age-related macular degeneration (AMD) through two years.
Comparison Of Avastin And Lucentis In Treating Age-Related Macular Degeneration
At two years, Avastin (bevacizumab) and Lucentis (ranibizumab injection), two widely used drugs to treat age-related macular degeneration (AMD), improve vision when administered monthly or on an as needed basis, although greater improvements in vision …
Disrupted Sleep May Increase Risk for Obesity, Diabetes
Short sleep duration and circadian disruption may
alter metabolism and therefore increase the risk of
obesity and diabetes, according to a study in Science
emTranslational Medicine/em.sup1/sup
Orfeu M. Buxton, PhD, of Harvard Medical School in
Boston,…
Glaucoma Specialists Believe Preservatives in Glaucoma Medications Exacerbate OSD
Results of a survey recently conducted by the Working
Group on Preservatives Toxicity in Glaucoma Medications,
an advisory panel of glaucoma experts, revealed that,
although some progress has been made in ophthalmologists’
awareness of preservative t…